Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for nonmedical reasons in psoriatic disease patients - 21/04/16
Doi : 10.1016/j.jaad.2016.02.941
Le texte complet de cet article est disponible en PDF.
Mark Lebwohl, Mount Sinai School of Medicine, New York, NY, United States; Martha Skup, AbbVie Inc, North Chicago, IL, United States; Murali Sundaram, AbbVie Inc, North Chicago, IL, United States; Hongbo Yang, Analysis Group, Inc, Boston, MA, United States; Elizabeth Faust, Analysis Group, Inc, Boston, MA, United States; Andrew Kageleiry, Analysis Group, Inc, Boston, MA, United States; Jingdong Chao, AbbVie Inc, North Chicago, IL, United States; Douglas Wolf, Atlanta Gastroenterology Associates, Atlanta, GA, United States
Le texte complet de cet article est disponible en PDF.| Design, study conduct, and financial support for the study were provided by AbbVie Inc. AbbVie participated in the interpretation of data, review, and approval of the abstract; all authors contributed to the development of the publication. |
© 2016
Publié par Elsevier Masson SAS.
Vol 74 - N° 5S1
P. AB240 - mai 2016 Retour au numéro
Article précédent
- Clinical characteristic of pustular psoriasis in 53 Thai patients
- Comparative effectiveness of biologic therapy in the Psoriasis Longitudinal Assessment and Registry (P.S.O.L.A.R.) Study
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?